Evidence map›Paper›PMID 32436120›Full record

ArticleDigestive diseases and sciences2021

A Phenome-Wide Analysis of Healthcare Costs Associated with Inflammatory Bowel Diseases.

Winston Cai, Andrew Cagan, Zeling He, Ashwin N Ananthakrishnan

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06328452 (Risk Factors and Impact of Metabolic Dysfunction -Associated Steatotic Liver Disease in Patients With Inflammatory Bowel Disease), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06328452 unknown statusnot on this mapstarted 2024, after this paper: background citation

Risk Factors and Impact of Metabolic Dysfunction -Associated Steatotic Liver Disease in Patients With Inflammatory Bowel Disease

TypeobservationalSponsorAssiut UniversityRan2024 to 2025Enrolled120ConditionsMetabolic Dysfunction-associated Steatotic Liver DiseaseArmsFibroScan
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Winston CaiBronx Science, New York City, NY, USA.
Andrew CaganResearch IS and Computing, Partners HealthCare, Charlestown, MA, USA.
Zeling HeDepartment of Biostatistics, Harvard School of Public Health, Boston, MA, USA.
Ashwin N AnanthakrishnanDivision of Gastroenterology, Crohn's and Colitis Center, Massachusetts General Hospital, 165 Cambridge Street, 9th Floor, Boston, MA, 02114, USA. aananthakrishnan@mgh.harvard.edu.ORCID 0000-0002-9436-1821
Harvard University · USBronx High School of Science · USMass General Brigham · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCrohn's disease (CD) and ulcerative colitis (UC) are associated with considerable direct healthcare costs. There have been few comprehensive analyses of all IBD- and non-IBD comorbidities that determine direct costs in this population.

methodsWe used data from a validated cohort of patients with inflammatory bowel disease (IBD). Total healthcare costs were estimated as a sum of costs associated with IBD-related hospitalizations and surgery, imaging (CT or MR scans), outpatient visits, endoscopic evaluation, and emergency room (ER) care. All ICD-9 codes were extracted for each patient and clustered into 1804 distinct phecode clusters representing individual phenotypes. A phenome-wide association analysis (PheWAS) was performed using logistic regression to identify predictors of being in the top decile of costs.

resultsOur cohort is comprised of 10,721 patients with IBD among whom 50% had CD. The median age was 46 years. The median total cost per patient is $11,203 (IQR $2396-30,563). The strongest association with total healthcare costs was intestinal obstruction without mention of hernia (p = 5.93 × 10

conclusionsSurrogate markers suggesting possible irreversible bowel damage and active disease demonstrate the greatest influence on IBD-related healthcare costs.

Indexed as

AdultCohort StudiesColitis, UlcerativeCost of IllnessCrohn DiseaseFemaleHealth Care CostsHospitalizationHumansInflammatory Bowel DiseasesMaleMiddle AgedCostCrohn’s diseaseElectronic health recordsUlcerative colitis

Identifiers

PMID32436120
OpenAlexW3026925112

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.